News articles about Ardelyx (NASDAQ:ARDX) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ardelyx earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.4867513160959 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald set a $12.00 price target on Ardelyx and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Zacks Investment Research upgraded Ardelyx from a “sell” rating to a “buy” rating and set a $6.50 price target for the company in a report on Friday, November 10th. Leerink Swann restated an “outperform” rating and set a $13.00 price target on shares of Ardelyx in a report on Tuesday, October 17th. Finally, ValuEngine downgraded Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.75.

Ardelyx (NASDAQ ARDX) traded up $0.10 during midday trading on Friday, reaching $5.70. The company had a trading volume of 217,215 shares, compared to its average volume of 491,070. Ardelyx has a 52 week low of $4.05 and a 52 week high of $16.30.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.10. During the same period in the prior year, the company earned ($0.65) earnings per share. analysts predict that Ardelyx will post -2.05 earnings per share for the current fiscal year.

In related news, COO Reginald Seeto sold 10,008 shares of Ardelyx stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.47% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Ardelyx (ARDX) Earning Somewhat Favorable Media Coverage, Study Finds” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/19/ardelyx-ardx-earning-somewhat-favorable-media-coverage-study-finds.html.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Stock Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related stocks with our FREE daily email newsletter.